Attah Abraham, Peterson Chelsea, Jacobs Max, Bhagavatula Rama, Shah Deep, Kaplan Robert, Samhouri Yazan
Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA 15212, USA.
Hematol Rep. 2024 May 9;16(2):295-298. doi: 10.3390/hematolrep16020029.
Heparin products are frequently used in the inpatient setting to prevent and treat venous thromboembolism, but they simultaneously put patients at risk of developing heparin-induced thrombocytopenia (HIT). The 4Ts score determines the pretest probability of HIT. Diagnosis is made with a screening antiplatelet factor (PF4) immunoassay and the serotonin-release assay (SRA) as a confirmatory test. Anti-PF4 assays have high sensitivity (98%) but lower specificity (50%) and result in frequent false-positive tests. We present a rare case from our institution of a patient with anti-PF4-Polyanion ELISA-negative, SRA-positive HIT and describe the challenges in making a timely diagnosis in this case.
肝素产品常用于住院患者中预防和治疗静脉血栓栓塞,但它们同时使患者有发生肝素诱导的血小板减少症(HIT)的风险。4Ts评分可确定HIT的预测试概率。诊断通过筛查抗血小板因子(PF4)免疫测定进行,血清素释放试验(SRA)作为确证试验。抗PF4测定具有高灵敏度(98%)但特异性较低(50%),并导致频繁出现假阳性检测结果。我们报告了我院一例抗PF4-多聚阴离子ELISA阴性、SRA阳性的HIT患者的罕见病例,并描述了该病例及时诊断所面临的挑战。